CeriBell, Inc. (NASDAQ:CBLL) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analyst sentiment is moderately bullish: Seven brokerages rate CeriBell “Moderate Buy,” with four buys, one strong buy, one hold and one sell. The average 12-month price target is $24.40, with recent targets ranging from $26 to $30.
• Shares are trading near their 52-week high: CBLL fell $0.13 to $24.87, compared with a 12-month range of $10.85 to $25.63. The stock’s market capitalization is approximately $954.6 million.
• The company remains unprofitable, while insiders have been selling: CeriBell reported a quarterly loss of $0.51 per share, missing estimates, despite revenue exceeding forecasts. Insiders sold 413,593 shares worth about $9.1 million over the past three months.

Shares of CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) have been given an average rating of "Moderate Buy" by the seven ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $24.40.

Several analysts have recently issued reports on the company. Raymond James Financial restated a "strong-buy" rating and issued a $29.00 price objective on shares of CeriBell in a research report on Thursday, September 3rd. Weiss Ratings raised shares of CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday. Canaccord Genuity Group boosted their price objective on shares of CeriBell from $25.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Barclays raised shares of CeriBell to a "neutral" rating in a research note on Tuesday, August 18th. Finally, BTIG Research reaffirmed a "buy" rating and issued a $30.00 target price on shares of CeriBell in a research note on Friday, September 11th.

CeriBell Price Performance

Shares of NASDAQ:CBLL traded down $0.13 during midday trading on Friday, hitting $24.87. 40,847 shares of the stock were exchanged, compared to its average volume of 342,233. CeriBell has a twelve month low of $10.85 and a twelve month high of $25.63. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The company has a 50 day moving average price of $21.51 and a 200-day moving average price of $19.79. The stock has a market cap of $954.55 million, a P/E ratio of -14.13 and a beta of 0.95.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.04). The business had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. On average, research analysts forecast that CeriBell will post -1.96 earnings per share for the current year.

Insider Transactions at CeriBell

In related news, Director Joseph Taylor sold 13,095 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $23.40, for a total transaction of $306,423.00. Following the transaction, the director directly owned 48,478 shares in the company, valued at approximately $1,134,385.20. This represents a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP David Foehr sold 9,255 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $24.25, for a total transaction of $224,433.75. Following the transaction, the vice president owned 34,144 shares in the company, valued at approximately $827,992. The trade was a 21.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 413,593 shares of company stock valued at $9,085,381. Corporate insiders own 17.70% of the company's stock.

Hedge Funds Weigh In On CeriBell

A number of hedge funds have recently made changes to their positions in CBLL. Strs Ohio purchased a new position in shares of CeriBell in the 1st quarter worth $27,000. Legal & General Group Plc purchased a new position in shares of CeriBell in the 2nd quarter worth about $53,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of CeriBell by 8,735.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,739 shares of the company's stock valued at $60,000 after purchasing an additional 2,708 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of CeriBell by 1,403.1% during the 4th quarter. Larson Financial Group LLC now owns 2,871 shares of the company's stock worth $63,000 after purchasing an additional 2,680 shares during the period. Finally, State of Wyoming acquired a new stake in CeriBell during the 1st quarter worth approximately $62,000.

About CeriBell

Ceribell, Inc NASDAQ: CBLL is a medical technology company focused on improving the detection and management of seizures and other neurological conditions in hospital settings. Its products are designed to make electroencephalography (EEG) more accessible at the point of care, particularly in emergency departments, intensive care units and other settings where conventional EEG testing may be delayed or difficult to obtain.

The company's primary offering is the Ceribell Rapid Response EEG system, which combines a portable EEG recorder, a simplified electrode headband and software for acquiring and reviewing brain-wave data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.